We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
- Authors
Swanson, Chad J.; Zhang, Yong; Dhadda, Shobha; Wang, Jinping; Kaplow, June; Lai, Robert Y. K.; Lannfelt, Lars; Bradley, Heather; Rabe, Martin; Koyama, Akihiko; Reyderman, Larisa; Berry, Donald A.; Berry, Scott; Gordon, Robert; Kramer, Lynn D.; Cummings, Jeffrey L.
- Abstract
B Correction: Alz Res Therapy 13, 80 (2021) b https://doi.org/10.1186/s13195-021-00813-8 Following the publication of the original article [[1]] files for Supplementary Appendices A and B were not included in the publication of the original article. B Supplementary Appendix A: b Study Protocol (BAN2401-G000-201--protocol.pdf) B Supplementary Appendix B: b Simulation Plan (simulation plan.pdf) The original article [[1]] has been updated. Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A protofibril antibody.
- Subjects
ALZHEIMER'S disease; CLINICAL trials; IMMUNOGLOBULINS; LECANEMAB
- Publication
Alzheimer's Research & Therapy, 2022, Vol 14, Issue 1, p1
- ISSN
1758-9193
- Publication type
Correction Notice
- DOI
10.1186/s13195-022-00995-9